GlassScriptPhysician profile
Karrie S Wolfe
NPI 1104175017
$2,412.18
in general payments reported to CMS, 2019-2025
32 companies · $608 in 2025
The $608 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $424 · 2023: $595 · 2024: $401 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.74 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $319.69 | 2021-2025 | Urolift |
| Pfizer INC. | $241.22 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $207.68 | 2025 | |
| Myovant Sciences INC. | $157.96 | 2021-2022 | |
| Urogen Pharma, INC. | $156.40 | 2022-2025 | Jelmyto |
| 180 Medical, INC. | $154.67 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $148.49 | 2021-2023 | Xiaflex, Aveed |
| Convatec INC. | $132.89 | 2022-2025 | |
| Edap Technomed INC | $109.26 | 2023 | |
| Endo USA, INC. | $90.94 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $82.78 | 2024 | Urgent PC Neuromodulation System |
| Sumitomo Pharma America, INC. | $64.53 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $53.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $48.66 | 2025 | |
| Merck Sharp & Dohme LLC | $45.99 | 2023-2025 | Keytruda, Lynparza, Welireg |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $45.20 | 2021-2025 | Xyosted |
| Abbvie INC. | $43.97 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $36.06 | 2024-2025 | |
| Coloplast Corp | $27.88 | 2023-2024 | Speedicath |
| Glaxosmithkline, LLC. | $22.39 | 2023 | Shingrix, Arexvy |
| Ambu INC. | $21.62 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.61 | 2022 | |
| Medtronic, INC. | $21.11 | 2023 | Interstim |
| Procept Biorobotics Corporation | $20.92 | 2023 | Aquabeam Robotic System |
| Alexion Pharmaceuticals, INC. | $20.82 | 2024 | Ultomiris |
| Urovant Sciences INC | $19.93 | 2022 | |
| Janssen Biotech, INC. | $18.27 | 2025 | Erleada |
| Tolmar, INC. | $18.25 | 2024 | |
| Telix Pharmaceuticals | $17.02 | 2022 | |
| Photocure INC | $15.47 | 2025 | Cysview |
| Immunitybio, INC. | $13.78 | 2024 | |
| Progenics Pharmaceuticals, INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karrie Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.